09 April 2008
Update on topical pain relief project
Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, can provide the following update on its topical pain relief project, TPR100, using Futura's proprietary trans-dermal delivery technology, DermaSys®.
Completion of clinical studies to evaluate drug delivery using Futura's Dermasys ® technology has been extended to complete formulation optimisation. Commercial negotiations are continuing on a non-exclusive basis.
We will provide further updates to shareholders at the earliest opportunity.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
+44 (0) 1483 685 670
james.barder@futuramedical.com
www.futuramedical.com
Nominated Adviser:
Nomura Code Securities Limited
Phil Walker / Giles Balleny
Tel: +44 (0) 20 7776 1200
For media enquiries please contact:
Buchanan Communications Limited
Mark Court / Stasa Filiplic / George Prassas
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.